Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus PRAVASTATIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus PRAVASTATIN SODIUM.
ATORVALIQ vs PRAVASTATIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Lowers LDL cholesterol, triglycerides, and increases HDL cholesterol by upregulating hepatic LDL receptor expression.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
10-40 mg orally once daily; initiate at 10-20 mg and titrate based on response.
None Documented
None Documented
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
Terminal elimination half-life is 1.3-2.6 hours; despite short half-life, HMG-CoA reductase inhibition persists longer due to effective hepatic extraction and enterohepatic recirculation.
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Primarily biliary (60% as unchanged drug and metabolites), with approximately 20% renal excretion; fecal elimination accounts for about 70% of total clearance.
Category C
Category D/X
Statin
Statin